

Psychopharmacology

And Substance Abuse News



DIVISION 28

AMERICAN PSYCHOLOGICAL ASSOCIATION

FROM THE PRESIDENT'S DESK

—Suzette M. Evans

As I am writing this column, it dawns on me that I am about halfway through my term as President of our division. Time is passing very quickly and not a day goes by that I am not reminded of my duties to Division 28 (some days are better than others).

The most important upcoming event is the 2007 Convention in San Francisco. Our current Program Chair, Ryan Vandrey, should be congratulated for doing a splendid job of putting together an exciting program for this year (details enclosed in the newsletter). However, upon close inspection of the program content and speakers, it struck me that the overwhelming majority of symposia and posters sponsored by Division 28 were clinical in nature—either treatment-oriented or human laboratory research. This reflects submissions, not Ryan's selection bias. The more I mused on this and thought back over previous conferences in the past ten years, it seemed that fewer preclinical researchers were presenting at APA within Division 28. Though I did not go back through the last ten years' programs to empirically confirm my gut feelings, I did the next best semi-scientific approach—I conducted a brief poll and sent it out to the Division 28 listserv.

I learned some important things from conducting this poll. First, you need to keep



it short and simple. Second, invariably the questions are not all flawless. However, here are the results of the poll:

1) There were 103 respondents. At first the response excited me, but then I realized that our division has 686 members, and the listserv goes out to others, including student affiliates. Thus, the overall response was at best 15%.

2) The table at the top of page 2 summarizes the mean number of APA conferences that respondents attended and the mean number of times respondents presented at APA over the past 5 years. These data are shown for the entire sample and then broken down by clinical researchers, preclinical researchers (research with non-human animals) and NA (e.g., those who were primarily in practice, teaching, retired, etc).

Continued on page 2

Respondents	# APA Conferences Attended in past 5 Years	# APA Conferences Presented at in past 5 Years
Total Sample (103)	1.57	1.31
Clinical Researchers (56)	2.23	1.80
Preclinical Researchers (31)	1.09	0.88
NA Category (16)	0.88	0.44

Overall, respondents attended the APA conference only 31% of the time in the last five years; this was substantially lower for preclinical researchers and the NA category compared to the clinical researchers. Therefore, my "hypotheses" were confirmed: within Division 28, fewer preclinical researchers, compared to clinical researchers, are attending and presenting at APA.

3) As expected, the most common reasons for not attending the APA conference included the fact that the conference is too large and diverse, there are too many competing conferences to attend, and travel money is limited. However, several other

reasons resonated with me, including many comments that the conference has become less scientific, that there is not enough preclinical research, and that sessions are poorly attended. I do agree with the latter two reasons, but I think we can take steps to improve that.

One approach is to encourage preclinical scientists to submit symposia to Division 28. This is an excellent opportunity, particularly for students, postdoctoral fellows, and junior faculty to give oral presentations, rather than posters. Many people may not be aware of this, but NIDA and NIAAA, along with Divisions 28 and 50, co-sponsor a poster session at APA

and provide travel awards to early career scientists. In addition, in conjunction with CARE (Committee on Animal Research and Ethics) and two other divisions (6 and 45), we sponsor an Interdivisional Mentoring Program specifically geared towards mentoring junior-level preclinical researchers; up to 8 awardees are selected and provided \$1,000 to help cover travel and registration expenses for APA. Wendy Lynch, a preclinical researcher herself, will be our Program Chair for the 2008 convention. One of her goals is to specifically solicit submissions for symposia and posters which will balance human and laboratory research, focusing on translational research.

Poor attendance at sessions is something that attendants themselves need to make a concerted effort to improve. It is disheartening to submit an abstract, be scheduled to participate in a symposium, or be an award winner, only to have a handful of people in the audience. I know, be-



cause I've been one of those speakers where the audience consisted of the other speakers and colleagues who felt obligated to attend. It's true that APA can be large and unwieldy, but if we want to keep people involved and keep science as a part of our program, we need to show our support for speakers by turning out to hear them.

4) On a more positive note, although few members attend and present at APA, they remain members of APA, and, more importantly, Division 28. I can only assume that for these individuals, attending the annual conference is not the primary reason they continue their membership; rather, they recognize the importance of being part of such a strong organization.

Other Items

There are some other items that I should mention at this time.

1) Currently, APA recognizes Psychopharmacology as a proficiency in

professional psychology. Many of you may not be aware, but the original petition for a proficiency in Psychopharmacology was submitted to APA by our Division, along with Divisions 31 (State, Provincial, and Territorial Psychological Association Affairs), 42 (Psychologists in Independent Practice), 50 (Addictions), and 55 (American Society for the Advancement of Pharmacotherapy). The Commission for the Recognition of Specialties and Proficiencies in Professional Psychology (CRSPPP) has informed us that our current petition ends in August 2008. Therefore, a renewal of this petition is required by January 1, 2008. We have had several conference calls among the involved divisions as to: 1) whether we should reapply for proficiency or apply for a specialty, and 2) which division should take the lead. I am happy to report that a consensus was reached: Division 28 will take the lead in renewing the

proficiency in Psychopharmacology. In the meantime, steps will be made, led by Division 55, to move toward a new specialty (perhaps in Medical Psychology, as a distinction from Psychopharmacology).

2) Election results are in! John Roll is the new President-elect for 2008 and Stacey Sigmon is our new Member-at-Large for 2008-2010. I personally want to extend my congratulations to both. Not to diminish their enthusiasm for winning, the number of voters who turned out at the polls was relatively low, compared to our membership. Alas, this is probably not much different from the low turnout at our national elections.

Sincerely,

Suzette M. Evans, Ph.D., 2007 President of Division 28 (se18@columbia.edu)

EDITORIAL POLICY

Psychopharmacology and Substance Abuse News is a thrice-yearly publication of Division 28. It is devoted to keeping its members informed about the activities of Division 28 and to news and comments concerning all aspects of psychopharmacology and substance abuse. Articles, comments, announcements, and advertisements should be sent to John Roll at johnroll@wsu.edu. 7/07 118687



ANNOUNCING THE 2007 DIVISION 28 AWARD WINNERS!

Anthony Liguori, Ph.D., Division 28 Awards Chair

Please join me in congratulating this year's Division 28 award winners, all of whom will be receiving their awards and presenting lectures on the morning of August 17 at the 2007 APA Convention in San Francisco. Please reserve the hours of 8-10 a.m. to begin the Division 28 program by attending these three presentations.

The Outstanding Dissertation Award (sponsored by Friends Research Institute) winner is **Nicole M. Avena, Ph.D.**, of The Rockefeller University. Dr. Avena is already contributing extensively to the pharmacology literature, with over 10 peer-reviewed publications. Her dissertation research, conducted at Princeton University, investigated the abuse potential of glucose in rodents. Dr. Avena found a deprivation effect in which abstinence from glucose subsequently led to increased glucose intake.

Richard Foltin, Ph.D. will introduce Dr. Avena's lecture and present her with an engraved plaque and a \$250 check. The title of Dr. Avena's presentation is *Behavioral and Neuro-*

chemical Evidence of Sugar Dependence in Rats.

The Wyeth Young Psychopharmacologist Award winner is **William E. Fantegrossi, Ph.D.**, Assistant Professor in the Yerkes National Primate Center at Emory University. Dr. Fantegrossi received graduate training from 2006 Brady-Schuster Award (sponsored by MED Associates) winner James H. Woods, Ph.D., and postdoctoral training from Dr. Woods and Michael R. Kilbourn, Ph.D., all at the University of Michigan. Dr. Fantegrossi's current research examines the behavioral pharmacology and toxicology of illicit designer drugs such as ecstasy. He also has served on the Drug Evaluation Committee of the College on Problems of Drug Dependence (CPDD) for the past five years.

Joshua A. Lile, Ph.D. will introduce Dr. Fantegrossi's lecture and present him with an engraved plaque and a \$250 check. The title of Dr. Fantegrossi's presentation is *Behavioral Pharmacology of MDMA and Its Enantiomers.*

The Brady-Schuster Award (sponsored by MED Associates) win-

ner is **Robert L. Balster, Ph.D.** of Virginia Commonwealth University. Dr. Balster is an internationally renowned behavioral pharmacologist with over 250 publications. He has mentored over 25 graduate students and postdoctoral trainees. Among his many research contributions are state-of-the-art methods for studying the abuse potential of inhalants and the pharmacology of phencyclidine (PCP). He is Editor-in-Chief of *Drug and Alcohol Dependence*, Past-President of both Division 28 and CPDD, and a Fellow of the American College of Neuropsychopharmacology.

Charles R. Schuster, Ph.D. will introduce Dr. Balster's lecture and present him with an engraved plaque and a \$500 check. The title of Dr. Balster's presentation is *Drugs Made Me Do It: The Development and Application of Drug Discrimination Research.*

If you are interested in being considered for one of these awards, or if you know of a deserving candidate, please contact aliguori@wfubmc.edu. Nominations are due at the end of the year, but it is never too early to prepare a nomination packet!

UPDATE ON THE 2007 CONVENTION

Ryan Vandrey, Program Chair

The annual convention of the American Psychological Association is scheduled for August 17-20 in San Francisco, CA. Division 28 has an outstanding program covering a broad range of topics related to psychopharmacology and substance abuse that you will not want to miss. If you have not already done so, you should book

your flights and accommodations as soon as possible!

The complete convention program is now available on the web at <http://forms.apa.org/convention/>. Below you will find a list of programming from Division 28 and related sessions from other divisions. Enclosed with this newsletter, you will also

find a detailed brochure highlighting a number of events sponsored by NIDA and NIAAA. Please contact me (rvandrey@jhmi.edu) if you have any questions about the meeting or would like me to send you a hard copy of the programming information. I hope to see everyone in San Francisco!!!



A FEW TIPS OF THE TRADE FOR FIRST TIME PAPER/POSTER PRESENTERS

Attending a professional meeting is one of the most fulfilling experiences one can take pleasure in. It is a time to disseminate knowledge, exchange ideas, gain new information and enjoy the company of your fellow researchers and clinicians. For first-time conference presenters however, this can be an intimidating experience.

The main thing that you should remember is that this is an academic environment. Exchanges at professional meetings should be constructive and collegial, not adversarial so, you shouldn't feel worried about "looking dumb." While you may be corrected, this is generally done in a very professional, non-intimidating manner. We all make mistakes and we all have to learn from them! You can avoid making too many mistakes and saying, "I don't know" too many times by being prepared. Below, I've listed a few pointers for first-time paper/poster presenters.

Paper Presentations

1.) Timing: You will be allotted a certain amount of time for your presentation. Keep slides simple so they convey only the most important information. William W. Stoops, Ph.D., suggests that you plan on spending 1 minute per slide. This way, you can pace yourself.

2.) Practice: Whether you practice in front of your dog or the bathroom mirror, practicing your talk will make you feel more comfortable in front of the audience, help you avoid getting "stuck," and ensure that you stay within your time-frame.

3.) Presence: Avoid fidgeting, using ums and ahs (it's OK to have a silent pause), and reading directly from your slides or notes while in front of the audience. Also, pay attention to the volume of your voice; you want to be heard but you also don't want to bust people's eardrums.

4.) Preparedness: This goes for both paper and poster presentations. Prior to the meeting, brush up on the literature that supports the rationale for the conduct of the study as well as for the conclusions drawn from the results. You'll feel much better about yourself when you can say, "Yes that was a between-groups design" instead of, "I'm really not sure."

Poster Presentations

1.) Tact: In a poster session, you will be talking one on one with people who are interested in your research. Be sure that you are standing at your poster at

the correct time and that you are available for discussion. When someone makes a suggestion, politely say that you'll consider it or discuss the matter further with him/her (if you feel comfortable). Some people may want you to summarize the study verbally. It's a good idea to have a scripted version in your head that covers all of the main points. The best advice is simply to maintain a professional demeanor.

2.) Readiness: Bring a back-up disc just in case something happens to your poster and you need to run to the printer the morning before the session. Bring thumbtacks and Velcro, in the event that these supplies are not provided, you'll be prepared. Bring 20-25 copies of your poster or keep a list of e-mail addresses of people who would like a copy of your poster.

I hope that these tips are helpful for first-time conference presenters. If any student has suggestions or requests for future news columns please, share your ideas with me (arvans2@uky.edu). I hope to see you all in San Francisco!

—Andrea R. Vansickel, APA Division
28 Student Representative



EXTENDED PROGRAM SUMMARY FOR DIVISIONS 28, 50, AND RELATED SESSIONS AT THE 2007 APA CONVENTION

Thursday, August 16th

1:00 pm – 5:00 pm • San Francisco Marriott Hotel— Nob Hill Room B

NIDA Grant Writing Workshop (pre-registrant's only)
To register please contact Ryan Vandrey (rvandrey@jhmi.edu)

6:00 pm – 8:00 pm San Francisco Marriott Hotel— Sierra Suite G

Div. 28 Executive Committee Meeting

Friday, August 17th

8:00 am – 8:50 am • Moscone Center Room 212

Outstanding Dissertation Award

Introduction: Richard W. Foltin, PhD, Columbia University in the City of New York

Recipient: Nicole M. Avena, PhD, Princeton University; *Behavioral and neurochemical evidence of sugar dependence in rats.*

Young Psychopharmacologist Award

Introduction: Joshua A. Lile, PhD, University of Kentucky

Recipient: William E. Fantegrossi, PhD, Yerkes National Primate Research Center; *Behavioral pharmacology of MDMA and its enantiomers.*

9:00 am – 9:50am • Moscone Center Room 224

Brady-Schuster Award

Introduction: Charles R. Schuster, PhD, Loyola University Chicago

Recipient: Robert L. Balster, PhD, Virginia Commonwealth University; *Drugs made me do it: The development and application of drug discrimination research.*

8:00 am – 9:50 am • Moscone Center Room 2005

Practical Challenges Integrating Evidence-Based Practices Into Addiction Treatment Programs (*CE Session)

Chair: Nancy A. Piotrowski, PhD, Capella University

Joan Zweben, PhD, East Bay Community Recovery Project;
*Implementing EBPs in a Community Treatment Program:
Beyond Instruction*

Michael S. Levy, PhD, CAB Health & Recovery Services, Inc.;
*EBP in Community Treatment Programs: Let's Not Forget
the Basics*

Gregory S. Brigham, PhD, University of Cincinnati—Maryhaven;
*Valuing Ongoing Evaluation in Adopting Buprenorphine—
Naloxone Short-Term Taper*

Harry K. Wexler, PhD, National Development and Research Institutes, Inc.; *Implementing Evidence-Based Practices for
Addiction Treatment in Criminal Justice Settings*

Discussants: Harold I. Perl, PhD, National Institute on Drug Abuse, and Daniel R. Kivlahan, PhD, VA Puget Sound Health Care System

10:00 am – 11:50 am • Moscone Center Room 272

Modulation of Stimulants by Estradiol and Progesterone— Rodents to Humans

Chair: Suzette M. Evans, PhD, Columbia University in the City of New York

Justin J. Anker, BA, University of Minnesota—Twin Cities; *Estrogen and Progesterone Modulation of Cocaine-Seeking Behavior in Female Rats*

Ming Hu, PhD, University of Michigan—Ann Arbor; *Role and Mechanism of Gonadal Hormones on Cocaine-Related Sex Differences*

Nancy K. Mello, PhD, McLean Hospital; *Effects of Estradiol on Cocaine Behavior by Female Nonhuman Primates*

Emma Childs, PhD, University of Chicago; *Interactions Between Menstrual Cycle Phase and Amphetamine in Women*

Suzette M. Evans, PhD, Columbia University in the City of New York; *Modulation of Smoked Cocaine by Oral Micronized Progesterone in Humans*

10:00 am – 11:50 am • Moscone Center Room 3002

Contemporary Perspectives on Mechanisms of Behavior Change in Alcohol Treatment

Robert B. Huebner, PhD, National Institute on Alcohol Abuse and Alcoholism; *Mechanisms of Behavior Change: An Overview*

Jon Morgenstern, PhD, Columbia University Medical Center; *Rethinking Paradigms That Inform Behavioral Treatment Research for Drinking Problems*

Carlo C. DiClemente, PhD, University of Maryland Baltimore County; *Personal Process Mechanisms and Moderators in Drinking Behavior Change*

Mark L. Willenbring, MD, National Institute on Alcohol Abuse and Alcoholism; *Broader Picture of Mechanisms of Behavior Change*

11:00 pm – 11:50 pm • Moscone Center Rooms 232 and 234

Effective Collaboration—Pharmacologically Trained Psychologists and Physicians (Div 55)



11:00 – 12:50pm • Moscone Center Rooms 220

Behavioral Pharmacology of Stimulants—Pharmacological and Nonpharmacological Factors

Chair: Raymond C. Pitts, PhD, University of North Carolina—Wilmington

Raymond C. Pitts, PhD, University of North Carolina—Wilmington; *Effects of d-Amphetamine on Behavior Maintained by Signaled and Unsignaled Delayed Reinforcement*

Amy L. Odum, PhD, Utah State University; *Sensitization Develops to the Effects of Repeated d-Amphetamine on Responding of Rats Under Random-Ratio and Random-Interval Schedules of Food Delivery*

Jonathan W. Pinkston, PhD, University of Kansas; *Some Effects of the Route of Administration on Amphetamine's Ability to Induce Focused Stereotypy*

Joshua A. Lile, PhD, University of Kentucky; *Human Cocaine Choice: Effects of Dose and an Alternative Reinforcer*

12:00 pm – 1:50 pm • Moscone Center Room 3001

Neuroimaging Research: Implications for the Neuro-Feedback Treatment of Substance Abuse

Co-Chairs: Meyer D. Glantz, PhD, National Institutes of Health, and Steven J. Grant, PhD, National Institute on Drug Abuse

Anna Rose Childress, PhD, University of Pennsylvania; *Visualizing the Struggle to Stop (Inhibit) Cue-Induced Drug Craving*

Martin Paulus, MD, University of California—San Diego; *Brain Systems Involved in Decision Making Predict Drug Relapse*

Clinton D. Kilts, PhD, Emory University; *Brain Systems Involved in Inhibitory Control and Response to Substance Abuse Treatment*

Christopher deCharms, PhD, Omneuron, Inc.; *Real Time Functional fMRI for Control of Pain*

Cameron S. Carter, MD, University of California—Davis; *Prospects for Training and Treatment of Brain Systems Involved in Cognitive Control*

12:00 – 1:50pm • Moscone Center Room 2002

Harm Reduction Therapy for Substance Users—An Emerging Evidence-Based Approach

Chair: Frederick Rotgers, PsyD, Philadelphia College of Osteopathic Medicine

Patt Denning, PhD, Harm Reduction Therapy Center; *Core Principles of Harm-Reduction Informed Treatment*

Jeannie Little, MSW, Harm Reduction Therapy Center; *Self-Determination Theory in Working With Oppressed and Traumatized Clients*

Perri Franskoviak, PhD, Harm Reduction Therapy Center; *Harm Reduction on the Fly: Applying the Principles of Harm Reduction Therapy in a Community Program*

G. Alan Marlatt, PhD, University of Washington; *Mindfulness Meditation, Harm Reduction, and the Middle Way*

1:00 pm – 1:50 pm • Moscone Center Room 2010

Tobacco Use Prevalence and Policies Among Military Trainees (Div 19)

1:00 – 1:50pm • Moscone Center Room 212

Emerging Models for Clinical Experience in Psychopharmacology (Div 55)

2:00 – 3:50pm • Moscone Center Room 3006

Psilocybin and Experimental Mysticism

Co-Chairs: Roland R. Griffiths, PhD, Johns Hopkins University School of Medicine, and Ralph W. Hood, Jr., PhD, University of Tennessee at Chattanooga

Ralph W. Hood, Jr., PhD, University of Tennessee at Chattanooga; *Set and Setting Effects in Experimental Studies of Mystical Experience*

William A. Richards, PhD, Johns Hopkins Bayview Medical Center; *Phenomenology and Potential Religious Import of States of Consciousness Facilitated by Psilocybin*

Roland R. Griffiths, PhD, Johns Hopkins University School of Medicine; *Psilocybin Occasions Mystical Experiences Having Sustained Spiritual Significance*

Matthew W. Johnson, PhD, Johns Hopkins University School of Medicine; *Human Psilocybin Research: Guidelines for Safety*

Discussant: Charles R. Schuster, PhD, Loyola University Chicago

2:00 pm – 3:50 pm • Moscone Center Room 2005

Adolescent Substance Use Decision Making—Innovative Approaches

Co-Chairs: Sandra A. Brown, PhD, University of California—San Diego, and Kristen G. Anderson, PhD, University of California—San Diego

Carl W. Lejuez, PhD, University of Maryland College Park; *Novel Behavioral Measures for Assessing the Development of Risk Behavior*

Jane Metrik, PhD, Brown University; *Marijuana's Acute Effects: Impulsive Decision Making, Disinhibition, and Risk Taking*

Kristen G. Anderson, PhD, University of California—San Diego; *Adolescent Substance-Use Decision Making: Process-Oriented Assessment of Relapse*

Mark G. Myers, PhD, VA San Diego Healthcare System; *Adolescent Cigarette Smoking Self-Change: Focus Groups for Instrument Development*

Discussant: Sandra A. Brown, PhD, University of California—San Diego

4:00 pm – 4:50 pm • San Francisco Marriott Hotel—Nob Hill Rooms C and D

Div 21 Address - Phil Ackerman, PhD

Why Is It So Difficult to Bridge Science and Application? Tales From the Editorial Trenches



EXTENDED PROGRAM SUMMARY FOR DIVISIONS 28, 50, AND RELATED SESSIONS AT THE 2007 APA CONVENTION

Saturday, August 18th

8:00 am – 9:50 am • Moscone Center Room 3011

Division 28 New Fellows Addresses

- Chair: Steve Heishman, PhD, National Institute on Drug Abuse
Scott D. Lane, PhD, University of Texas Health Science Center at Houston; *Factors Influencing Risky Decision Making in Humans*
David Shurtleff, PhD, National Institute on Drug Abuse; *Current and Future Directions of Basic Drug Addiction Research: A NIDA Division Director's Perspective*
Carroll W. Hughes, PhD, University of Texas Southwestern Medical Center at Dallas; *Role of Fluoxetine Levels in Childhood Major Depressive Disorder*
Sara J. Nixon, PhD, University of Florida; *Neurocognitive Consequences: The Bigger Picture*
Dennis McCarty, PhD, Oregon Health and Science University; *Improving Treatment Processes for Alcohol and Drug Disorders*

8:00 am – 9:50 am • Moscone Center Room 2004

Women's Issues and Substance Abuse Treatment (*CE Session)

- Co-Chairs: Susan M. Gordon, PhD, Seabrook House, and Carmen L. Rosa, MS, National Institute on Drug Abuse
Theresa Winhusen, PhD, University of Cincinnati; *Motivational Enhancement Therapy for Pregnant Substance Users*
Denise Hien, PhD, Columbia University in the City of New York; *Implementing Trauma-Focused Group Therapy in Community Drug Treatment Settings*
Susan Tross, PhD, New York State Psychiatric Institute; *HIV/STD Sexual-Risk Behavior in Women in Drug Treatment Programs*
Discussant: Kathleen Brady, MD, PhD, Medical University of South Carolina

10:00 am – 10:50 am • San Francisco Marriott Hotel— Yerba Buena Salon 10

Division 28 Presidential Address

- Suzette M. Evans, PhD, Columbia University in the City of New York; *Vulnerability to Drug Abuse in Women: The Role of Multiple Risk Factors*

11:00 am – 11:50 am • San Francisco Marriott Hotel— Yerba Buena Salon 10

Division 28 Business Meeting

2:00 – 3:50pm • Moscone Center Room 2007

Treatment of Drug-Use Disorders in Dual-Diagnosis Patients (*CE Session)

- Chairs: Meyer D. Glantz, PhD and David Epstein, PhD, National Institute on Drug Abuse
Paula D. Riggs, PhD, University of Colorado at Denver and Health Sciences Center; *Treating Conduct Disordered Adolescents With Substance Use and Psychiatric Comorbidity*
Kenzie L. Preston, PhD, NIDA Intramural Research Program; *Treatment of Polydrug Dependence: Heroin and Cocaine*
Alan S. Bellack, PhD, University of Maryland Baltimore; *Engagement, Motivation, and Treatment Strategies for People With Dual Disorders*
Frances R. Levin, MD, Columbia University College of Physicians and Surgeons; *Treatment of Comorbid ADHD and Substance Abuse Disorders*
Edward Nunes, MD, Columbia University College of Physicians and Surgeons; *Treatment of Comorbid Affective and Substance Abuse Disorders*
Discussant: Meyer D. Glantz, PhD, National Institute on Drug Abuse

4:00 pm – 5:50 pm • Moscone Center Room 2010

Diffusion of Evidence-Based Substance Abuse Treatments— Research and Clinical Perspectives

- Chair: James L. Sorensen, PhD, University of California—San Francisco
James L. Sorensen, PhD, University of California—San Francisco; *In the Diffusion of Innovations Everyone Changes: Linking Practice With Scientific Research*
Varda Shoham, PhD, University of Arizona; *Therapist Training and Development Research: A Missing Piece?*
Joseph Gudysh, PhD, University of California—San Francisco; *Adoption of Motivational Interviewing and Motivational Enhancement Therapy: Organizational Readiness*
Cynthia L. Arken, PhD, Wayne State University; *Financing and Diffusion of Substance Abuse Treatment*
Joan Zweben, PhD, University of California—San Francisco; *Evidence-Based Practices: Key Issues for Treatment Programs*
Discussant: Carmen L. Masson, PhD, University of California—San Francisco

5:00 pm – 5:50 pm • Moscone Center Room 222

Div 6 New Fellow Address, Rick A. Bevins, PhD.

- Investigation of Nicotine as a Pavlovian Cue*



EXTENDED PROGRAM SUMMARY FOR DIVISIONS 28, 50, AND RELATED SESSIONS AT THE 2007 APA CONVENTION

Sunday, August 19th

8:00 am – 9:50 am • Moscone Center Room 270

Extinction Learning: Application to Drug Addiction (*CE Session)

Co-Chairs: David Shurtleff, PhD, National Institute on Drug Abuse, and Paul Schnur, PhD, National Institute on Drug Abuse

Ronald E. See, PhD, Medical University of South Carolina; *Neural Substrates of Drug-Seeking Behavior After Forced Abstinence or Explicit Extinction Training in an Animal Model of Relapse*

Kathleen M. Kantak, PhD, Boston University; *Navigating Extinction of Drug Addiction: Role of the Hippocampus*

Cynthia A. Conklin, PhD, University of Pittsburgh Medical Center; *Smoking Cues and the Challenge of Extinction-Based Treatment*

Joseph McClernon, PhD, Duke University Medical Center; *Extinction-Based Smoking Cessation Treatment Attenuates Event-Related Brain Responses to Smoking Cues: Results of a Preliminary fMRI Study*

10:00 am – 10:50 am • Moscone Center Room 222

Measuring Drug Reinforcement in Humans— Methodologies, Current Findings, and Implications

Chair: William W. Stoops, PhD, University of Kentucky

William W. Stoops, PhD, University of Kentucky; *Progressive Ratio Schedules and Drug Reinforcement in Humans: Current Findings*

Matthew W. Johnson, PhD, Johns Hopkins University; *Multiple Choice Procedure for Drug Reinforcement: Comparing Different Drugs*

Mark K. Greenwald, PhD, Wayne State University School of Medicine; *Translating Individuals' Drug Choices Into Microeconomic Demand: Method and Applications*

Discussant: Richard W. Foltin, PhD, New York State Psychiatric Institute

10:00 am – 10:50 am • Moscone Center Halls ABC

Poster Session I for Division 50

11:00 am – 11:50 am • Moscone Center Halls ABC

Poster Sessions for Divisions 28 & 50

12:00 pm – 12:50 pm • Moscone Center Room 250

Drug Abuse and Homelessness Among Women at Risk for HIV
(Div 35)

12:00 pm – 12:50 pm • Moscone Center Room 226

Building a Better Carrot—Enhancing Incentives for Successful
Treatment Outcomes (Div 18)

12:00 pm – 12:50 pm • Moscone Center Room 301

Prenatal Tobacco Exposure—Impact on Cognitive and
Emotional Processes Across Development (Div 40)

12:00 pm – 12:50 pm • Moscone Center Room 232 & 234

Conversation About Diversifying Science (Div 6)

12:00 pm – 12:50 pm • Moscone Center Room 262

Drug—Drug Interactions: Pharmaceuticals, OTCs, Herbal and
Food Products (Div 55)

12:00 pm – 1:50 pm • Moscone Center Room 2007

Innovations in the Prevention and Treatment of Marijuana
Abuse Among Adolescents

Co-Chairs: Denise D. Walker, PhD, University of Washington,
and Alan J. Budney, PhD, University of Arkansas for
Medical Sciences

Denise D. Walker, PhD, University of Washington; *Motivational Enhancement Therapy for Adolescent Marijuana Use: An Efficacy Study*

Christine M. Lee, PhD, University of Washington; *Feasibility and Efficacy of a Brief, Web-Based Personalized Feedback Intervention for Marijuana*

Elizabeth J. D'Amico, PhD, RAND Corporation; *Project CHAT: The Impact of a Brief Motivational Intervention for High-Risk Teens in Primary Care*

Therese K. Killeen, PhD, Medical University of South Carolina College of Medicine; *Contingency Management for Adolescents With Marijuana Use Disorders*

Discussant: Alan J. Budney, PhD, University of Arkansas for
Medical Sciences

2:00 pm – 2:50 pm • Hilton San Francisco Hotel Continental Parlor 2

Improving Access and Retention for Addiction Treatment

Co-Chairs: Dennis McCarty, PhD, Oregon Health and
Science University, and Elaine Cassidy, PhD, Robert Wood
Johnson Foundation

Elaine Cassidy, PhD, Robert Wood Johnson Foundation; *Network for the Improvement of Addiction Treatment: An Overview*

Jennifer P. Wisdom, PhD, MPH, Oregon Health and Science
University; *Process Improvement and Data-Driven Decisions*

Traci Rieckmann, PhD, Oregon Health and Science University; *Rapid Cycles for Organizational Change and Quality Improvement*

Discussant: Dennis McCarty, PhD, Oregon Health and
Science University



**3:00 pm – 3:50 pm • Hilton San Francisco Hotel
Continental Parlor 2**

**Understanding College Student Drinking—Current Trends
and Protective Strategies**

Co-Chairs: Joseph LaBrie, PhD, Loyola Marymount University,
and Eric Pedersen, MA, Loyola Marymount University

Eric Pedersen, MA, Loyola Marymount University; *Examination of
Prepartying Behavior Among College Students*

Joseph LaBrie, PhD, Loyola Marymount University; *Drinking
Games in the College Environment*

Melissa Lewis, PhD, University of Washington; *Observations of
Helping Behavior for Symptoms of Alcohol Poisoning Among
College Students*

Matthew P. Martens, PhD, State University of New York at
Albany; *Protective Behavioral Strategies: Possibilities in Reducing
Heavy Drinking Among College Students*

Discussant: Mary E. Larimer, PhD, University of Washington

**4:00 pm – 6:00 pm • Hilton San Francisco Hotel
Continental Ballroom 4**

**NIDA and NIAAA-Sponsored Early Career Social Hour
and Poster Session**

Monday, August 20th

**8:00 am – 4:00 pm • Hilton San Francisco Hotel—
Franciscan Room B**

**CE Workshop: Tobacco Cessation: Offering Effective Treatment
to Your Clients**

To register go to www.apa.org and click “CE Enrollment”

8:00 am – 9:50 am • Moscone Center Room 2010

**HIV and HCV Transmission Risks in Noninjecting Drug Users
(* CE Session)**

Co-Chairs: Randall E. Rogers, PhD, University of Vermont, and
Stacey C. Sigmon, PhD, University of Vermont

Robert E. Booth, PhD, University of Colorado at Denver and
Health Sciences Center; *Sex Risks: Opiate Injectors, Stimulant
Injectors, and Crack Cocaine Smokers*

James A. Peck, PsyD, University of California—Los Angeles;
*Methamphetamine Abuse and HIV Among MSM: Where Are
We Going*

Kendall Bryant, PhD, National Institute on Alcohol Abuse and
Alcoholism; *Developing New Intervention Strategies for Alcohol
and AIDS Research*

Carl A. Latkin, PhD, Johns Hopkins Bloomberg School of Public
Health; *HIV and HCV Transmission From Injectors to Noninjectors*

Discussant: Alan Neaigus, PhD, National Development and
Research Institutes, Inc.

8:00 am – 9:50 am • Moscone Center Room 2009

**Creating the Environmental Context for Sustained Alcohol and
Drug Recovery**

Chair: Douglas L. Polcin, EdD, MS, Alcohol Research Group

Leonard A. Jason, PhD, DePaul University; *Environmental and
Systemic Approaches to Reducing Relapse Following Discharge
From Treatment*

Gantt P. Galloway, PhD, St. Luke's Hospital; *Does a Supportive
Environment Facilitate Sustained Recovery? Six-Month Outcomes
of Clean and Sober Housing*

Christine Timko, PhD, Stanford Medical Center; *Evaluating an
Intervention to Engage Homeless, Substance-Abusing Veterans in
Treatment*

Discussant: Rudolf H. Moos, PhD, Stanford University

10:00 am – 11:50 am • Moscone Center Room 2003

**HIV/AIDS-Related Research in the NIDA Clinical Trials Network
(*CE Session)**

Chair: Donald A. Calsyn, PhD, University of Washington

Robert E. Booth, PhD, University of Colorado at Denver and
Health Sciences Center; *HIV/HCV Risk-Reduction Interventions in
Drug Detoxification and Treatment Settings*

Susan Tross, PhD, New York State Psychiatric Institute; *HIV/STD
Safer Sex Groups for Women in Substance Abuse Treatment*

Donald A. Calsyn, PhD, University of Washington; *HIV/STD
Safer-Sex Groups for Men in Substance Abuse Treatment*

James L. Sorensen, PhD, University of California—San Francisco;
Future HIV Research Efforts Planned for the Clinical Trials Network

Lisa Metsch, PhD, University of Miami Leonard M. Miller School
of Medicine; *Rapid Testing and Counseling Research Within
the CTN*

10:00 – 10:50am • Moscone Center Room 2005

**Role of Club Drugs in the Lives of Gay and Bisexual Men
(Div 44)**

**12:00 – 1:50pm • Moscone Center Rooms
252/254/256**

**Assessing, Moderating, and Modifying Implicit Cognitive
Processes in Alcohol and Drug Misuse in Adolescents and
Young Adults**

Co-Chairs: Reinout W. Wiers, PhD, Maastricht University, and
Susan Ames, PhD, University of Southern California

Marvin Krank, PhD, University of British Columbia—Okanagan;
*Preventing Substance-Use Transitions in Early Adolescents Using
Feedback From Implicit Cognition*

Susan Ames, PhD, University of Southern California; *Comparison
of Indirect Assessments of Association as Predictors of Marijuana
Use Among At-Risk Adolescents*

Jerry L. Grenard, MA, University of Southern California; *Working
Memory Moderates the Predictive Effects of Drug-Related
Associations*

Sherry H. Stewart, PhD, Dalhousie University; *Mood-Induced
Activation of Implicit Alcohol Cognition in Subtypes of Internally
Motivated Drinkers*

Reinout W. Wiers, PhD, Maastricht University; *Assessing and
Retraining Automatic-Action Tendencies in Heavy Drinkers*

Discussant: Ken Sher, PhD, University of Missouri—Columbia



CALL FOR NOMINATIONS FOR APA FELLOWS

STEPHEN HEISHMAN
FELLOWS CHAIR

The Executive Committee of Division 28 seeks nominations for Fellow status in APA. Any APA and Division 28 member who has made outstanding contributions to psychopharmacology or substance abuse is eligible. Below is a list of eligibility criteria that APA and our division use when considering nominees. These are minimum standards under the APA bylaws, so all criteria must be met.

- Receipt of a doctoral degree based in part on a psychological dissertation or from a program primarily psychological in nature,
- Membership in APA for at least one year and a current member of Division 28,
- Active engagement at the time of nomination in the advancement of psychology in any of its aspects,
- Five years of acceptable professional experience subsequent to the granting of the doctoral degree, and
- Evidence of unusual and outstanding contribution or performance in the field of psychopharmacology or substance abuse.

The nominee should be on a focused career path, with typically a minimum of 35-40 publications and ideally independent grant funding.

If you wish to nominate someone or yourself for APA Fellow, please send me the person's name, mailing address, phone number, email address, and CV.

I can send anyone a list of the members and fellows in Division 28. If you have questions concerning criteria or the steps involved in the nomination process, don't hesitate to contact me. I look forward to hearing from you.

Stephen J. Heishman
National Institute on Drug Abuse
5500 Nathan Shock Drive
Baltimore, MD 21224
heishman@nih.gov

DIVISION 28 THANKS THE FOLLOWING FOR THEIR CONTINUED SUPPORT:

MERCK
(corporate membership support)

•
Wyeth Research
(Young Psychopharmacologist Award support)

•
Friends Research Institute, Inc.
(Dissertation Award support)

•
MED Associates
(Brady-Schuster Award support)



RESEARCH TRAINING AT THE UNIVERSITY OF MICHIGAN

UNIVERSITY OF MICHIGAN ADDICTION
RESEARCH CENTER (UMARC)

The Addiction Research Center invites applications from Ph.D.s and M.D.s for its NIAAA funded postdoctoral research training program. UMARC is the research arm of the Section on Substance Abuse (www.med.umich.edu/psych/sub) within the Department of Psychiatry, and it currently houses 23 projects addressing issues pertaining to the etiology, course, clinical manifestations, and treatment of alcoholism and alcohol problems. The university provides an unusually strong methodological infrastructure for trainees, and a research environment that is rich in interdisciplinary collaborations. An interdisciplinary faculty from the Departments of Psychiatry, Psychology, Statistics, Human Genetics, Pharmacology, and Emergency Medicine, the Institute for Social Research, and a number of other university-wide centers and institutes provides a broad range of mentored research opportunities. UMARC's activities are focused in six areas: I. Developmental Psychopathology and Genetics; II. Neuroimaging and Neurophysiological Research; III. Treatment Research; IV. Health Services Research; V. Prevention and Early Intervention; and VI. Research on Sleep and Sleep Problems as Related to Substance Use Disorder.

Current projects are in all six areas. Mentoring faculty include Kristen L. Barry, Ph.D., Frederic C. Blow, Ph.D., Kirk J. Brower, M.D., Margit Burmeister, Ph.D., Stephen T. Chermack, Ph.D., Mary M. Heitzeg, Ph.D., Jeffrey C. Long, Ph.D., Susan A. Murphy, Ph.D., Elizabeth A. R. Robinson, Ph.D., John E. Schulenberg, Ph.D., Maureen A. Walton, M.P.H., Ph.D., James H. Woods, Ph.D., Jon-Kar Zubieta, Ph.D., and Robert A. Zucker, Ph.D. A larger group of other faculty affiliated with the center compliment the program and are available for specialized work. Fellows in recent years have been drawn from a number of specialty areas: behavior genetics, sociology, cognitive, clinical, community, and developmental psychology, developmental psychopathology, behavioral pharmacology, addiction medicine, emergency medicine, and neuroscience. Fellowships offer the opportunity to develop an integrated research program

and enhance skills necessary for a successful academic/research career. In addition to the primary emphasis on research development, fellows participate in a broad menu of content-relevant courses and workshops to develop their methodological expertise. Trainees also complete a Web-based research responsibility training called PEERRS. Fellows attend quarterly UMARC Fellow meetings, monthly research seminars, a regular series of UM Substance Abuse Research Center (UMSARC) pro-seminars and interdisciplinary lectures, and Department of Psychiatry Grand Rounds.

Fellows must be U.S. citizens or permanent residents with a Ph.D. or M.D. degree. Appointments typically are for two years of training, although a third year appointment is sometimes available. Salaries are commensurate with prior postdoctoral experience and NRSA regulations. Applications will be considered as received for appointments in the 2007–2008 year, although an earlier start date is preferable. Send a CV, three letters of reference, and a detailed cover letter describing your research interests, potential project foci for the fellowship period, and longer term career goals to:

Robert A. Zucker, Ph.D.
Director, University of Michigan
Addiction Research Center
Rachel Upjohn Building
4250 Plymouth Road
Ann Arbor, MI 48109-5740
zuckerra@umich.edu

Postdoctoral Fellowships in Alcohol and Addiction Research

Department of Psychological Sciences
University of Missouri-Columbia
and the Midwest Alcoholism
Research Center

The Department of Psychological Sciences at the University of Missouri-Columbia (MU) has openings for up to **three postdoctoral research fellows in alcohol and addictions research.**

Faculty preceptors include: Lynne Cooper (drinking motives, alcohol and sexual behavior, adolescent risk-taking, personality, diary and longitudinal methodologies), Tom Piasecki (tobacco dependence and withdrawal, alcohol X tobacco interaction, hangover, ecological momentary assessment), Ken Sher (etiological processes in alcohol use disorders, comorbidity, alcohol and adult development, college student drinking), Wendy Slutske (behavioral genetics of alcoholism, externalizing behavior disorders, pathological gambling), Tim Trull (alcoholism and personality, personality disorder comorbidity), Phil Wood (alcohol use and cognitive development, alcohol use and schooling, quantitative methodology), Denis McCarthy (drinking motives, underage use, drinking and driving, behavioral pharmacogenetics of alcohol), Bruce Bartholow (alcohol and social cognition, social neuroscience), Dennis Miller (behavioral pharmacology of nicotine and other drugs), and Matt Will (behavioral pharmacology of appetitive behavior including eating and psychoactive substance use). Postdoctoral research fellows will undertake advanced training in addictions and pursue their own research interests under the supervision of faculty sponsors. MU's addiction training is closely affiliated with the Midwest Alcoholism Research Center (MARC) based at Washington University in St. Louis (PI: Andrew Heath). Postdoctoral fellows will have the opportunity to become involved with MARC research activities in addition to those activities based on the MU campus. At least one position will be internally funded and international candidates will be considered. The other positions are on an NIAAA Research



Training Grant, and the applicant must be a United States resident or citizen. Candidates must hold a Ph.D. or other doctoral degree relevant to the study of the psychology of addiction. These positions are for up to two years and start date is negotiable.

Send vita, up to five representative reprints, a cover letter describing your research interests and training goals, and three letters of reference to: Addiction Research Training, c/o Carol Waudby, Dept. of Psychological Sciences, 200 S. 7th Street, University of Missouri, Columbia, MO 65211. Inquiries can be made to Ken Sher, 573-882-4279, SherK@missouri.edu.

The University of Missouri-Columbia does not discriminate on the basis of race, color, religion, national origin, ancestry, sex, age, disability, status as disabled veteran, or veteran of Vietnam era.

Harvard Medical School- McLean Hospital Alcohol and Drug Abuse Research Center

Behavioral Science Laboratory

Instructor/Assistant Professor Behavioral Pharmacology

Applications are invited for a junior faculty research position (tenure-track) at the Harvard Medical School in the Behavioral Science Laboratory at the Alcohol and Drug Abuse Research Center, McLean Hospital. This is an excellent opportunity for a well-trained, productive, behavioral or biological scientist (Ph.D. or M.D./Ph.D.) to join an ongoing Behavioral Science Research program and to develop independent research projects supported by extramural funding. The scientist would participate in an ongoing research program to evaluate new pharmacotherapies for the treatment of cocaine abuse and to examine sex/gender factors in drug abuse.

Experience in preclinical behavioral pharmacology research involving drug discrimination and drug self-administration is essential. Responsibilities will include conducting research and supervision of postdoctoral fellows and research assistants. Macintosh computer

skills are desirable. There are no formal teaching requirements. Applicants should have at least two years of postdoctoral experience and be qualified for an appointment at the instructor/assistant professor level. Salary is commensurate with experience. Review of applications will begin immediately and continue until the position is filled.

The Alcohol and Drug Abuse Research Center at McLean Hospital is an interdisciplinary basic and clinical research program concerned with evaluating the safety and effectiveness of new pharmacotherapies for drug abuse and sex/gender differences in substance abuse. Research at the center currently emphasizes the behavioral pharmacology of substance abuse, the neuroendocrine concomitants of cocaine and nicotine abuse, and the effects of drugs on the brain as assessed by functional magnetic resonance imaging (fMRI). The McLean Hospital is an affiliate of the Harvard Medical School and the Massachusetts General Hospital, located in Belmont, a suburb of Boston. For more information about this research program, go to www.mclean.harvard.edu/research/adarc.

Please send a curriculum vita, reprints of five recent papers, a brief statement about your research training, interests, and career goals, and the names of three references (including complete mailing and e-mail addresses and telephone numbers) to:

Nancy K. Mello, Ph.D.
Professor of Psychology (Neuroscience)
Co-Director, Alcohol and Drug Abuse
Research Center
McLean Hospital
115 Mill Street
Belmont, MA 02478

*McLean Hospital is an Equal Opportunity/
Affirmative Action/ADA Employer.
A member of the Partners Healthcare System.*

Postdoctoral Position in Addiction Research

Outstanding fellowship positions (2-3 years) are available in a new, productive, and growing research center with opportunities to join the faculty. Participate in the development, conduct, and publication of studies such as delay discounting, behavioral economics of drug reinforced behavior, computerized treatments of drug abuse, and develop new research opportunities. Fellows can also participate in research using brain-imaging techniques. Applicants must have completed doctoral training in psychology or related field and have research experience. Individuals from disadvantaged groups are encouraged to apply. Competitive stipends. Send letter of interest, vita, and letters of reference to: Warren K. Bickel, Ph.D., Center for Addiction Research, College of Medicine in alliance with the College of Public Health, University of Arkansas for Medical Sciences, 4301 W. Markham St., # 843, Little Rock, AR 72205; tel: 501-526-7810; e-mail: wbickel@uams.edu.



Postdoctoral Position, University of Pittsburgh Medical Center, Pennsylvania

A postdoctoral position in the behavioral pharmacology of nicotine in humans may be available in the laboratory of Dr. Kenneth A. Perkins at the University of Pittsburgh. This position is funded through NHLBI. Ongoing NIDA-supported projects focus on: 1) environmental modulation of nicotine responses and tobacco self-administration, 2) individual differences associated with sensitivity to nicotine or smoking, including gender, genetic, and personality factors, and 3) development of short-term procedures for evaluating the efficacy of medications for smoking cessation.

Interested candidates should send a C.V. and letter of interest to Dr. Perkins at the following address:

Kenneth A. Perkins, Ph.D.
Department of Psychiatry
University of Pittsburgh
Medical Center
3811 O'Hara Street
Pittsburgh, PA 15213

Voice: 412-246-5395
Fax: 412-246-5390
perkinska@upmc.edu
myprofile.cos.com/perkinsk31

Postdoctoral Position:

Apply experimental analysis of behavior to addiction.

Outstanding fellowship positions (2-3yrs) are available in new and growing research center with opportunities to join the faculty. Participate in the development, conduct, and publication of studies such as delay discounting, behavioral economics of drug reinforced behavior, computerized treatments of drug abuse, and also develop new research opportunities. Fellows can also participate in research using brain-imaging techniques. Successful fellows will have the opportunity to join faculty. Applicants must have completed doctoral training in psychology or related field and have research experience. Individuals from disadvantaged groups are encouraged to

apply. Competitive stipends (early \$40k). Send letter of interest, vita, and letters of reference to: Warren K. Bickel, Ph.D., Center for Addiction Research, College of Medicine, University of Arkansas for Medical Sciences, 4301 W. Markham St., # 843, Little Rock, AR 72205; Tel: (501) 526-7810; Email: wbickel@uams.edu

Postdoctoral Research Fellowships, Johns Hopkins University, Baltimore, Maryland

Postdoctoral research fellowships in stimulating, productive program with excellent resources. Prepare as independent investigator.

HUMAN LABORATORY—behavioral and clinical pharmacology of abused drugs (abuse liability, self-administration, cognitive function, neuroimaging); anti-drug-abuse medications development. Opioids, cocaine, anxiolytics, alcohol, caffeine, nicotine, hallucinogens/psychedelics, MDMA, club drugs.

CLINICAL TRIALS—testing medications, verbal and behavioral therapies (esp. incentive/contingency/motivation-based), and combinations; psychiatric comorbidity research; addiction and pregnancy/women. Opioid, cocaine, tobacco, mixed/other dependencies.

Eligibility: U.S. citizen, permanent resident. A broad range of backgrounds are appropriate from clinical/counseling to experimental/neuroscience.

NIH stipend levels: \$37K - 51K+.

Start Date: Flexible.

Faculty: George Bigelow, Roland Griffiths, Maxine Stitzer, Eric Strain, Ken Silverman, Robert Brooner, Miriam Mintzer, Una McCann, et al.

Contact: George Bigelow; BPRU, Behavioral Biology Research Center, 5510 Nathan Shock Drive, Johns Hopkins Bayview Campus, Baltimore, Maryland 21224-6823, 410-550-0035, bigelow@jhmi.edu, www.bpru.org

Department of Psychiatry, University of Vermont

A postdoctoral research fellowship is available immediately at the University of Vermont to help oversee a newly-funded NIDA R01 grant to develop an efficacious smoking cessation intervention among methadone-maintained (MM) patients. Prevalence of cigarette smoking among MM patients is more than three-fold that the general population and is associated with increased morbidity and mortality. Despite this, little is known about how to effectively help MM patients to quit smoking. We have been developing an intensive intervention with behavioral (contingency management) and pharmacotherapy (bupropion) components to promote smoking abstinence among MM patients. If proven to be effective, the potential for dissemination will be substantial, as MM is one of the only treatment modalities that adhere to a uniform set of state and federal regulations. The postdoctoral fellow would join a productive, internationally-recognized program of drug abuse/behavioral pharmacology research. Applicants must have completed doctoral training in psychology or a related discipline and be U.S. citizens or permanent residents. Salary is competitive commensurate with experience.

For more details, please contact Dr. Stacey Sigmon at stacey.sigmon@uvm.edu. Interested candidates should forward a curriculum vitae and letter of interest to Dr. Stacey Sigmon, University of Vermont, SATC-UHC Room 1415, 1 South Prospect Street, Burlington, VT 05401. The University of Vermont is an affirmative action and equal opportunity employer.



The Department of Psychiatry and Behavioral Sciences at Johns Hopkins University School of Medicine

There is an opening for an associate or assistant professor with a primary interest in substance abuse treatment and research.

Candidates must have a M.D. or Ph.D., prior administrative experience, and evidence of a productive and fundable research program. This position will direct a large, publicly-funded drug treatment program for 350+ opiate-, cocaine-, and alcohol-dependent patients. The successful candidate will have overall clinical and administrative responsibility for the program, including management of 50+ employees, proposal writing, program representation at the Johns Hopkins Hospital and outside agencies, and oversight of regulatory activities. The applicant also is expected to have an active research program, ideally focused on intervention/outcomes projects with opiate-dependent patients.

Applicants should submit a cover letter including statements of their administrative and research experiences, their curriculum vitae, representative publications, and three letters of recommendation to Mary E. McCaul, Ph.D., at mmccaul1@jhmi.edu or JHH Program for Alcoholism & Other Drug Dependencies, 911 N. Broadway, Baltimore, MD, 21205. Information on the Department and JHUSOM is available at www.hopkinsmedicine.org/Psychiatry.

Applicant interviews will begin on April 1, 2007. Women and racial/ethnic minorities are especially encouraged to apply.

Notice of Vacancy for Assistant Professor of Psychology Position Washington State University Department of Psychology Pullman, Washington

RANK: Assistant Professor

SALARY: Commensurate with experience

LENGTH OF APPOINTMENT:

Academic tenure-track permanent

APPLICATION DEADLINE: Postmarked by November 15, 2007

POSITION BEGINS: August 16, 2008

QUALIFICATIONS: Applicants are sought with research programs and teaching interests in Alcohol and Drug Abuse, either basic, preclinical or clinical. The ideal candidate will teach undergraduate and graduate courses in statistics/research methods, biopsychology and psychopharmacology. Candidates will have earned a PhD before date of hire in biopsychology, neuroscience, pharmacology or related fields. Candidates must have the ability to: (a) develop and maintain a productive research program; (b) supervise thesis and dissertation research of graduate students; (c) teach undergraduate and graduate courses; and (d) have demonstrated ability to work collegially and collaboratively with diverse internal and external constituencies.

LOCATION: Washington State University is a moderate-sized (17,000) land-grant institution located in rural southeastern Washington. The Department of Psychology actively participates in the Spokane Alliance for Medical Research in Spokane, WA, 82 miles north of Pullman, WA. Faculty work collaboratively with clinicians and researchers at the Spokane Heart Institute, Sacred Heart Medical Center, St. Luke's Rehabilitation Institute, Inland Northwest Health Services, Deaconess Hospital, the University of Idaho Child and Youth Study Center, as well as researchers in the Alcohol and Drug Abuse Program and Center for Integrated Biotechnology in Pullman.

APPLICATION PROCEDURE:

Letter of application, vita, reprints, statement of research interests, statement of teaching interests, and three letters of recommendation should be sent to:

Faculty Search Committee
Assistant Professor Position in
Alcohol and Drug Abuse
Washington State University
Department of Psychology
PO Box 644820
Pullman, WA 99164-4820

WSU employs only U.S. citizens and lawfully authorized non-U.S. citizens. All new employees must show employment eligibility verification as required by the U.S. Citizenship and Immigration Services. Washington State University is an Equal Opportunity/Affirmative Action educator and employer. People of color, women, Vietnam-era or disabled veterans, persons of disability and/or persons age 40 and older are encouraged to apply.

For specific inquiries, please contact:
Dr. Rebecca Craft, Chair of the Search Committee; craft@wsu.edu; 509-335-5040



John M. Roll, Ph.D.
Director
Washington Institute for Mental Illness
Research and Training
Washington State University Spokane
PO Box 1495
Spokane, WA 99210-1495

Visit our Web site:
www.apa.org/divisions/div28

DIVISION 28 EXECUTIVE COMMITTEE

ELECTED OFFICERS:

President	Suzette Evans
Past President	Alan Budney
President-Elect	Kim Kirby
President-Elect for Following Year	John Roll
Council Representative	Ken Sher
Members-at-Large	Dave Penetar
	Nancy Petry
	Mark Fillmore

APPOINTED OFFICERS:

Secretary	Drake Morgan
Treasurer	Jane B. Acri
Newsletter Editor	John Roll
Divisional Awards	Anthony Liguori
Membership	Joshua Lile
New Fellows	Steve Heishman
Convention Program Chairs	
San Francisco, CA	Ryan Vandrey

INFORMATION OFFICERS:

Archivist	Richard Foltin
*Electronic Information	Ronald W. Wood

COMMITTEE CHAIRS:

*Continuing Education	Marlyne Kilbey
-----------------------	----------------

APPOINTED LIAISONS/MONITORS:

*Student Representative	Andrea Vansickel
Board of Scientific Affairs	Alice Young
Board of Educational Affairs	M. Marlyne Kilbey
Liaison to Division 50	Linda Sobell
Liaison to Division 55	Mark Fillmore
Liaison to Science Directorate	Conrad Wong
Women's Network Representative	Nancy Piotrowski
Liaison to Committee on Animal Research and Ethics	James K. Rowlett
International Relations Committee	Mark Fillmore